newsfilter
← Latest News
PR Newswire·

Boston Scientific announces results for fourth quarter and full year 2025

BSXPEN
  • Boston Scientific reported Q4 2025 net sales of $5.286 billion, representing 15.9% reported growth, 14.3% operational growth, and 12.7% organic growth.
  • Full-year 2025 net sales totaled $20.074 billion, reflecting 19.9% reported growth, 19.2% operational growth, and 15.8% organic growth.
  • Q4 2025 GAAP net income was $672 million ($0.45 per share), while adjusted EPS reached $0.80 per share.
  • Full-year 2025 GAAP net income was $2.898 billion ($1.94 per share), with adjusted EPS of $3.06 per share.
  • Q4 2025 reported GAAP EPS of $0.45 fell below the guidance range of $0.48 to $0.52, while adjusted EPS of $0.80 exceeded the $0.77 to $0.79 range.
  • Cardiovascular segment sales grew 18.2% on a reported basis in Q4, while MedSurg sales increased 11.7%.
  • U.S. sales grew 17.0% in Q4, while EMEA sales rose 12.4% on a reported basis.
  • Management discontinued worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems in Q2 2025, which previously generated approximately $50 million per quarter globally.
  • The company received FDA approval and CE mark for the FARAPOINT™ Pulsed Field Ablation Catheter and initiated enrollment in the OPTIMIZE clinical trial.
  • Boston Scientific initiated the U.S. launch of the SEISMIQ™ Intravascular Lithotripsy System for peripheral artery disease and completed enrollment in the global FRACTURE IDE clinical trial for coronary disease.
  • The company received FDA 510(k) clearance for the TheraSphere 360™ Management Platform and CE mark for the MOSES Raydar™ Holmium Laser System.
  • Boston Scientific announced agreements to acquire Penumbra, Inc. for neurovascular solutions and Valencia Technologies Corporation for the eCoin® System.
  • The company completed the acquisition of Nalu Medical, Inc., developer of the Nalu Neuromodulation System for chronic pain.
  • For full-year 2026, the company estimates net sales growth of 10.5% to 11.5% reported and 10.0% to 11.0% organic, with adjusted EPS of $3.43 to $3.49.
  • For Q1 2026, the company forecasts net sales growth of 10.5% to 12.0% reported and 8.5% to 10.0% organic, with adjusted EPS of $0.78 to $0.80.